Navigation Links
Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta

EMERYVILLE, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) announced today the publication of results from its study on the inhibitory effect of tamoxifen on estrogen receptor beta (ERb) gene regulation. The results of the study, which will be published in Molecular and Cellular Endocrinology, demonstrate that tamoxifen inhibits the beneficial effects of ERb in the prevention of breast cancer cell proliferation.

"Tamoxifen has been successfully used to treat and prevent breast cancer. However, some breast tumors become resistant to its effects. So, it is critical to discover new estrogens that work through a different mechanism," stated Dr. Dale Leitman, the Principal Investigator of the study. "In this publication, we demonstrate that genes regulated by estrogen receptor beta, which has the positive effect of preventing the growth of breast cancer cells, are directly inhibited by tamoxifen. The inhibition of the beneficial effect of ERb in breast cancer cells could potentially lead to unwanted outcomes for breast cancer patients who are treated with tamoxifen."

Since the discovery of ERb, various studies have demonstrated that this receptor plays an important role in preventing breast cancer cell proliferation and tumor formation. These studies indicate that ERb is an important therapeutic target for drugs in development for breast cancer treatment and prevention. It has also been shown that approximately 40% of breast tumors express ERb, which suggests that this large subset of tumors could be inhibited by selective ERb drugs. This publication describes the effect of tamoxifen on hormone independent regulation of genes by ERb that are important in preventing the proliferation of breast cancer cells. The study shows that the pattern of gene expression by ligand independent regulation by ERb is inhibited by the administration of tamoxifen in estrogen dependent breast cancer cells. Moreover, this study shows that tamoxifen inhibits the recruitment of important coregulatory proteins to the receptor, which demonstrates that the effect observed is directly due to the interaction of tamoxifen with ERb.

"It is critical to develop new strategies to prevent and treat breast cancer. The knowledge we obtained from the positive clinical effects of tamoxifen combined with recent discoveries of the different roles played by the two estrogen receptors is critical for the future generation of therapies for this important indication," said Dr. Isaac Cohen, Chairman and CEO of Bionovo, Inc. "Bionovo has been developing methods to discover more selective drugs for breast cancer treatment and prevention and, to date, has identified numerous ERb-selective drugs. Dr. Leitman's study provides the biological rationale for advancing ERb drugs for the treatment of breast cancer, which we feel will be important, novel therapies for this indication."

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit:

Forward-Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

SOURCE Bionovo, Inc.

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
2. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
3. Bionovo Announces First Quarter 2009 Highlights and Financial Results
4. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
5. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
6. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
7. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
8. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
9. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
10. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
11. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
Post Your Comments:
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
Breaking Medicine News(10 mins):